135 related articles for article (PubMed ID: 34522875)
1. Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy.
Girardin F; Painter C; Hearmon N; Eddowes L; Kaiser S; Negro F; Vernaz N
JHEP Rep; 2021 Jun; 3(3):100279. PubMed ID: 34522875
[TBL] [Abstract][Full Text] [Related]
2. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.
Tskhomelidze I; Shadaker S; Kuchuloria T; Gvinjilia L; Butsashvili M; Nasrullah M; Gabunia T; Gamkrelidze A; Getia V; Sharvadze L; Tsertsvadze T; Zarqua J; Tsanava S; Handanagic S; Armstrong PA; Averhoff F; Vickerman P; Walker JG
Liver Int; 2023 Mar; 43(3):558-568. PubMed ID: 36129625
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of mass screening for Hepatitis C virus among all inmates in an Irish prison.
Ward Z; Mafirakureva N; Stone J; Keevans M; Betts-Symonds G; Crowley D; McHugh T; Avramovic G; Lambert JS; Vickerman P
Int J Drug Policy; 2021 Oct; 96():103394. PubMed ID: 34412938
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
[TBL] [Abstract][Full Text] [Related]
6. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
Manca F; Robinson E; Dillon JF; Boyd KA
Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
[TBL] [Abstract][Full Text] [Related]
7. Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination.
Shih STF; Stone J; Martin NK; Hajarizadeh B; Cunningham EB; Kwon JA; McGrath C; Grant L; Grebely J; Dore GJ; Lloyd AR; Vickerman P; Chambers GM
Open Forum Infect Dis; 2024 Feb; 11(2):ofad637. PubMed ID: 38344130
[TBL] [Abstract][Full Text] [Related]
8. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
9. [Cost-effectiveness of HCV testing strategies for hepatitis C elimination in general population in China].
Liu PC; Xu D; Ding GW; Zhao L; Yu JJ; Liu ZF; Li J
Zhonghua Liu Xing Bing Xue Za Zhi; 2024 Mar; 45(3):464-472. PubMed ID: 38514325
[No Abstract] [Full Text] [Related]
10. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z; Scott N; Nayagam S; Rwegasha J; Mbwambo J; Thursz MR; Brown AS; Hellard M; Lemoine M
Int J Drug Policy; 2022 Jan; 99():103458. PubMed ID: 34624732
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of glecaprevir/pibrentasvir regimen for treating Chinese patients with chronic hepatitis C genotype 1 and genotype 2 infection.
Zhou HJ; Wu G; Li JM; Naidoo N; Xie YX; Feng BL; Wang P; Luo JW
Ann Palliat Med; 2021 Oct; 10(10):10313-10326. PubMed ID: 34670381
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness of Hepatitis C Treatment for People Who Inject Drugs and the Impact of the Type of Epidemic; Extrapolating from Amsterdam, the Netherlands.
van Santen DK; de Vos AS; Matser A; Willemse SB; Lindenburg K; Kretzschmar ME; Prins M; de Wit GA
PLoS One; 2016; 11(10):e0163488. PubMed ID: 27711200
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
Mafirakureva N; Lim AG; Khalid GG; Aslam K; Campbell L; Zahid H; Van den Bergh R; Falq G; Fortas C; Wailly Y; Auat R; Donchuk D; Loarec A; Coast J; Vickerman P; Walker JG
J Viral Hepat; 2021 Feb; 28(2):268-278. PubMed ID: 33051950
[TBL] [Abstract][Full Text] [Related]
15. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness and Net Monetary Benefit of Olaparib Maintenance Therapy Versus No Maintenance Therapy After First-line Platinum-based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-mutated Ovarian Cancer in the Italian National Health Service.
Armeni P; Borsoi L; Fornaro G; Jommi C; Colombo N; Costa F
Clin Ther; 2020 Jul; 42(7):1192-1209.e12. PubMed ID: 32591103
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
18. Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A cost-effectiveness analysis.
Girardin F; Hearmon N; Negro F; Eddowes L; Bruggmann P; Castro E
J Viral Hepat; 2019 Feb; 26(2):236-245. PubMed ID: 30338887
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of national mandatory screening of all admissions to English National Health Service hospitals for meticillin-resistant Staphylococcus aureus: a mathematical modelling study.
Robotham JV; Deeny SR; Fuller C; Hopkins S; Cookson B; Stone S
Lancet Infect Dis; 2016 Mar; 16(3):348-56. PubMed ID: 26616206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
